The Margin podcast cover art

The Margin · Medical

ASC Valuation in 2027: Multiples, What Buyers Pay For and How Margin Moves the Price

Episode 32 · November 4, 2026 · 9 min

Two ASC centers can post identical revenue and sell for wildly different prices, and the reason comes down to one number buyers actually care about. We walk through the real 2027 multiple ranges, why margin confidence drives the check at closing, and the exact diligence packet buyers request before an LOI ever gets drafted.

Chapters:
0:06 Cold Open
0:49 The Multiple Is A Symptom
1:47 Why Margin Beats Size
3:11 What Buyers Actually Diligence
4:38 Quality Penalties And The Site Neutrality Tailwind
6:44 What To Do This Quarter
7:50 Close

Free guide, The 2027 ASC State of the Union: https://sigmatic.ai/guide
Book a free consultation: https://sigmatic.ai/contact

#asc #surgerycenter #ambulatorysurgery #healthcarefinance #orutilization #ascvaluation #ebitda #mergersandacquisitions

Chapters

  1. 00:06 Cold Open
  2. 00:49 The Multiple Is A Symptom
  3. 01:47 Why Margin Beats Size
  4. 03:11 What Buyers Actually Diligence
  5. 04:38 Quality Penalties And The Site Neutrality Tailwind
  6. 06:44 What To Do This Quarter
  7. 07:50 Close

Transcript

Read the full transcript Every episode is transcribed, searchable, and quotable. Plain text

Sigmatic: Here's a sentence that should make every A S C owner a little uncomfortable. Two centers can have the exact same revenue and sell for completely different prices. Not because one has better equipment, not because one has a nicer lobby. Because one of them runs at a thirteen percent EBITDA margin and the other runs at thirty percent. Same top line, wildly different check at closing. If you've ever wondered why valuation conversations feel like they're speaking a different language than your monthly P and L, this is why. Today we're talking about what actually sets the price on an ambulatory surgery center in twenty twenty seven, and spoiler, it is almost never what people think it is.

Sigmatic: Let's start with the range, because the range itself tells a story. Single specialty centers are trading around five to eight times EBITDA. Multi specialty centers, six to ten times. Multi site platforms, the big regional and national groups, eleven to seventeen times. Look at that spread. It is huge. And the easy explanation is that bigger is just better, that scale buys you a bigger number. A buyer is not pricing your revenue. Revenue is just a number on a page. A buyer is pricing the cash your center actually produces after you pay for supplies, labor, rent, and everything else that keeps the lights on. Then they apply a multiple based on how confident they are that cash shows up again next year, and the year after that. The multiple is the symptom. Margin confidence is the disease, or the cure, depending how you're running things.

Sigmatic: Here's where it gets specific, and honestly a little stark. Centers under three million dollars in net revenue post an average EBITDA margin of twelve point eight percent. Centers over nine million post thirty seven point three percent. That gap is documented by Surgical Information Systems. Well run centers of any size, regardless of how big they are, land in the twenty to thirty percent range according to ASC News. And the industry wide average, across centers of every size and every level of operational discipline, sits closer to fifteen point nine percent, that's from IBISWorld by way of Vertess. It is almost entirely operational. Block utilization. First case on time starts. Turnover time between cases. Supply cost per case. Staff hours per case. Denial rate. Days in accounts receivable. None of that is about how big your center is. It is about how tightly it is run. A buyer who sees documented case costs and clean scheduling discipline is buying a margin they can underwrite with confidence. A buyer who sees a center that finds out its own margin once a year, from a tax return, prices in the uncertainty. And that discount doesn't show up as one line item you can point to and argue about. It shows up baked into the multiple itself.

Sigmatic: Here's the part I think every administrator should hear, because it is basically a checklist you could be running right now, whether you plan to sell next year or never. Before a letter of intent gets priced, a buyer's diligence team asks for contribution margin by procedure, by surgeon, and by payer, not just revenue by procedure. They want block utilization and first case on time start rates by surgeon, trended over at least a year, not a snapshot. They want supply cost per case on your top twenty procedures, with implant cost broken out separately. They want your denial rate and days in accounts receivable, with the aging detail behind both numbers, not just the headline figure. They want to see your physician ownership structure and confirm every owner complies with the federal safe harbor conditions, including real case volume performed at the center, not just a name on a cap table. And they want to know whether your payer contracts on the new procedures added to the twenty twenty six covered list carry a negotiated commercial rate, or whether you're still pricing those off a blanket Medicare multiple. Now here's the thing that matters more than any single item on that list. A center that can hand over this whole packet in an afternoon is going through a completely different diligence process than one that needs six weeks to reconstruct it from scratch. That six week gap is not neutral information. It tells the buyer something about how you run the place day to day, separate from whatever the numbers actually say once they're assembled.

Sigmatic: Two more pieces that shape the number, and both are easy to miss if you're only looking at your own P and L. First, the CY twenty twenty six Medicare rule ties a two point six percent payment update to meeting the A S C Quality Reporting Program requirements. If you miss that reporting threshold, you lose two full percentage points off your annual update. A buyer reviewing three years of financials sees that swing immediately. Second, there's a tailwind worth knowing about, because buyers are already pricing it in. The CY twenty twenty six rule added five hundred sixty procedures to the A S C covered list, two hundred seventy one of them freed from the inpatient only designation, plus thirty five ancillary services. Site neutral payment policy, paying the same rate for the same service no matter where it happens, keeps narrowing the gap between hospital outpatient rates and A S C rates. Every procedure that moves from inpatient only to A S C eligible is addressable volume a buyer can underwrite into next year's pro forma. But only if your center can prove the contribution margin on that procedure before you ever add the case. Ownership structure matters here too. About sixty two percent of A S C market revenue sits in physician owned centers. Management companies commonly charge four to seven percent of net revenue on top of an equity stake, and a buyer underwrites that fee against the margin they're already paying for. A hospital joint venture trades a share of profit for referral stability, which can actually raise the price a health system is willing to pay, even when that same standalone center wouldn't command it on the open market. And regulatory friction still varies a lot by state. Thirty five states plus the District of Columbia run some form of certificate of need program, though several exempt A S Cs outright. A buyer comparing two otherwise identical centers, one in a certificate of need state and one without, is pricing the second one as easier to expand. That difference is part of the multiple too, even though it never shows up on a spreadsheet labeled multiple.

Sigmatic: So here's what we'd actually tell you to do, starting this quarter, whether a sale is on your radar or not. First, pull contribution margin by procedure, surgeon, and payer for the trailing twelve months, and use consumption data, what was actually opened and used in the O R, not what's sitting on a preference card. This is the single document every buyer and every bank is going to ask for first, so you might as well have it ready for your own board before anyone external asks. Second, calculate your own EBITDA margin and place it honestly against that benchmark range, twelve point eight percent to thirty seven point three percent. Know which side of that range you're sitting on before someone else tells you, because that conversation is a lot more comfortable when you already know the answer. Third, confirm your ownership structure meets the federal safe harbor conditions for every single physician investor, and get it documented in writing. It just requires deciding to run your center like someone is going to ask for this packet in an afternoon, because eventually, someone will.

Sigmatic: Here's the thing I want you to walk away with. The multiple isn't magic, and it isn't really about your revenue size either. It's a reflection of how confident a buyer can be that your margin repeats, and that confidence is built or lost in the operational details, block utilization, supply cost per case, how fast you can hand over a diligence packet. Those are all things you can work on starting Monday, with or without a buyer in the room. If you want to make your A S C more profitable, book a free consultation with us at sigmatic dot A I. And if you want the fuller picture on where this market is heading, grab our free guide, The Twenty Twenty Seven A S C State of the Union. The links are in the show notes. Thanks for spending this time with us on The Margin. We'll see you next episode.

After the episode

Want a more profitable ASC?

Book a free 30-minute consultation on your own numbers, or leave your email and we will send the 2027 guide first.

Make your ASC more profitable.

A free 30-minute consultation on your own numbers: where the margin is, what to fix first. No obligation.